Navigation Links
Oral drug sets a new survival standard for bone marrow cancer
Date:11/21/2007

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. The findings demonstrate that with Revlimid, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed. Rush University Medical Center took part in the U.S. study. Results of the study were published November 21 in the New England Journal of Medicine.

In the study, a total of 353 patients were enrolled at 44 centers. Of those patients, 177 were assigned to receive Revlimid (lenalidomide) plus dexamethasone, a steroid hormone, and 176 received a placebo plus dexamethasone. According to the study results, patients who received Revlimid had a median survival of 29.6 months, compared to 20.2 months for the placebo group. In the Revlimid group, 61 percent of patients responded to therapy as compared with 19.9 percent in the placebo group.

According to the International Myeloma Foundation, follow-up data from the U.S. study and a European study report even better results. Patients treated with Revlimid had a median survival of nearly three years (35 months), the longest median survival in this difficult to treat patient group.

"Myeloma, also called multiple myeloma, is of growing interest and concern," said Dr. Stephanie Gregory, the director of the section of Hematology at Rush University Medical Center. "Statistics show the number of diagnoses is increasing in the United States where most cancers are decreasing, and myeloma is being found in increasingly younger patients. These trends give us some urgency in having potent treatments to fight this disease."

Revlimid is an immunomodulatory agent, a drug that can modify or regulate the functioning of the immune system. It is the newest of what are called the novel therapies that have changed the outlook for myeloma patients. It is an oral drug that can be taken at home, and because it targets the cancer cells directly along with factors that support their growth, it does not have the difficult side effects associated with most chemotherapy.

"We are pleased that aggressive efforts to find effective treatments in what was considered a rare, little-known cancer, have led to drugs with broad implications for understanding, treating and eventually curing so many forms of the disease," said Susie Novis, president and co-founder of the International Myeloma Foundation. "Myeloma has been a difficult disease to cure, but with novel therapies we are developing effective, long-term treatments by using multiple drugs in sequence and in various combinations. The addition of a drug with the potency of Revlimid to this equation is especially important."

In Europe and the U.S. Revlimid has been approved for use in multiple myeloma, and in the U.S. it is also approved for a pre-leukemia condition called MDS. It is also being tested in other leukemias and lymphomas and even solid tumors.

Myeloma is a bone marrow cancer that attacks and destroys bone. It accounts for about 16,000 new cases of cancer each year. An estimated 56 thousand people in the United States are living with Myeloma and this year approximately 11,300 deaths from Myeloma are anticipated. While there is no known cure for myeloma, doctors have many approaches to help myeloma patients live better and longer.


'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Mediterranean Diet May Boost Alzheimers Survival
6. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
7. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
8. Communication in cancer world is key to survival
9. Molecular profiling can accurately predict survival in colon cancer patients
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
(Date:12/8/2016)... ... 2016 , ... STAT courier is pleased to announce that due to customer ... are expanding their presence in Dallas. One of the most exciting parts for STAT ... to the Dallas and Forth Worth market. STAT takes pride in treating their employees ...
(Date:12/8/2016)... AR (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Little Rock, has initiated ... Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ranks ...
(Date:12/8/2016)... MS (PRWEB) , ... December 08, 2016 , ... The ... serve commercial and residential clients in and around the Hancock County area, is announcing ... the Hancock County Food Pantry. , The Hancock County Food Pantry has worked for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... passage of the most comprehensive mental health systems reform legislation in more than ... the President, and the commitment of our elected officials to improving mental health ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Dec. 8, 2016  A new study by a ... use of opioid therapy to treat chronic pain is ... of more harmful consequences, including death. Palliative ... Zankhana Mehta , M.D., authored the study which ... opioid therapy. The study was published in the December ...
(Date:12/8/2016)... 2016 Information products and services provider ... Scopus , the world,s largest abstract and citation database of ... for journals from over 5,000 publishers. The new set of metrics ... to and when to adjust a journal,s editorial strategy. ... , , ...
Breaking Medicine Technology: